Introduction
============

The increasing number of major non-cardiac surgical interventions is considered a global challenge in health care.[@b1-tcrm-14-999] Extensive surgical intervention is associated with direct mechanical tissue injury, local hemorrhage, and ischemia, followed by hypoxemic cellular stress and ischemia--reperfusion injury[@b2-tcrm-14-999] leading to innate and adaptive immunity activation on the local and systemic levels.[@b3-tcrm-14-999] The dysregulation of the host response increases the number of infectious complications, impairs wound healing, and adversely affects other clinical outcomes, including hospital stay, mortality, and long-term cognitive functions.[@b3-tcrm-14-999]--[@b5-tcrm-14-999] The degree of postoperative inflammatory response can be estimated by several clinical parameters (eg, heart rate, respiratory rate, and body temperature) and laboratory markers, including white blood cell (WBC) count, C-reactive protein (CRP), and interleukin-6 (IL-6).[@b6-tcrm-14-999]--[@b8-tcrm-14-999] Clinical signs are unreliable and their sensitivity and specificity are low. WBC and CRP measurements are routine in clinical practice, but their kinetics are slow with low ability to differentiate sterile and infectious insults.[@b9-tcrm-14-999] IL-6 can be detected early, but its measurement is not widespread and thus it cannot be considered a routine biomarker.[@b10-tcrm-14-999]

Alarmins are a group of intracellular molecules immediately released or actively secreted after mechanical cell injury, infection, or inflammation. In extracellular space, they exhibit cytokine-like functions, initiating an inflammatory and repara-tive response.[@b11-tcrm-14-999] Thus, they represent first-line signal molecules that potentially reflect the degree of tissue injury.

Laparoscopic surgical procedures (LPSs) have several advantages over open surgery, including less invasiveness (ie, smaller incision) resulting in less postsurgical pain, reduced risk of infectious contamination, and faster functional recovery.[@b12-tcrm-14-999] LPSs are the standard of care in colorectal surgery due to cost-effectiveness and better outcomes (ie, hospital stay, number of complications) compared to open surgical procedures.[@b13-tcrm-14-999] However, LPSs also have some disadvantages, such as the need for greater surgeon experience, limited range of motion, poor depth assessment, absence of tactile sensation, use of tools that are less subtle in interactions with tissues compared to the hands of a surgeon, longer duration of surgery, and general anesthesia.[@b12-tcrm-14-999]

The role of alarmins in evaluating the degree of injury in relation to the type of procedure (LPS or open surgery \[LPT\]) in major abdominal surgery (MAS) has not yet been studied. The primary objective of the analysis was to compare the serum levels of alarmins and biomarkers between LPS and LPT in order to determine which of the procedures is more harmful. The secondary objectives were to compare alarmin and biomarker levels in cancer subgroups and find the relationship between the type of procedure and selected outcomes, specifically intensive care unit length of stay (ICU-LOS) and hospital length of stay (H-LOS).

Patients and methods
====================

Study design and patients
-------------------------

The prospective single-center study was conducted between June 2013 and June 2014. The study was approved by the Medical Ethics Committee of the University Hospital of Ostrava, Czech Republic (reference number: 435/2013). The committee waived the need for informed consent prior to surgery due to the non-interventional observational nature of the study. The Consolidated Standards Of Reporting Trials flow diagram of patient selection is given in [Figure 1](#f1-tcrm-14-999){ref-type="fig"}. The inclusion criteria were as follows: \>18 years of age, absence of sepsis at the time of admission, and elective MAS. After surgery, the patients were admitted to the intensive care unit of the Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Czech Republic. The exclusion criterion was pregnancy or life expectancy \<24 hours. Major surgery was defined as a procedure expected to last \>2 hours and/or an anticipated blood loss of \>500 mL.[@b14-tcrm-14-999] General treatment, including hemodynamic optimization, use of anti-infectives, analgesia, and other measures of standard supportive care, was provided by certified intensive care physicians according to the recommendations of the Czech Society of Intensive Care Medicine[@b15-tcrm-14-999] and the Society of Critical Care Medicine.[@b16-tcrm-14-999] The whole group of patients was divided according to the type of the procedure into LPS and LPT groups. Then, in order to obtain a more homogenous cohort, we selected patients undergoing surgery for cancer and divided them into LPS cancer and LPT cancer subgroups.

Study protocol and measurements
-------------------------------

Baseline, clinical, surgical, and outcome characteristics were obtained upon intensive care unit admission (day 0). The American Society of Anesthesiologists physical status classification before surgery was recorded. The severity of the condition was estimated using the Acute Physiology and Chronic Health Evaluation II on the first postoperative day (POD 1) and the Sequential Organ Failure Assessment on POD 1--3. The presence of systemic inflammatory response syndrome (SIRS) and sepsis at any time during the first three consecutive days after surgery was recorded according to the standard definitions valid at the time of the study.[@b17-tcrm-14-999] Outcome variables, such as postsurgical complications defined according to Clavien Dindo Classification, ICU-LOS, H-LOS, 30-day mortality, and in-hospital mortality, are given in [Table 1](#t1-tcrm-14-999){ref-type="table"}.

Blood samples for the analysis of serum levels of biomarkers (WBC, CRP, IL-6) and alarmins (S100A8, S100A12, HMGB1, HSP70 proteins) were collected from the central venous catheter at 6:00 a.m. on POD 1--3. The blood samples were allowed to clot for 30 min and the supernatant subsequently centrifuged at 3,500 rpm (2,500×*g*) for 10 min at 4°C. Serum concentrations of CRP (AU 5420; Beckman Coulter, Inc., Brea, CA, USA) and IL-6 (Immulite 2000; DPC, Los Angeles, CA, USA) were assayed immediately. The interassay coefficients of variation were 4.8% and 6.7% for CRP and IL-6, respectively. Blood samples for the analysis of alarmins were centrifuged (2,500×*g*) at 4°C for 6 min and then frozen and stored at −80°C until further analyses. The concentrations of S100A8 and HMGB1 were determined quantitatively by sandwich enzyme-linked immunosorbent assay or in-house assays (Biovendor-Laboratorni medicina, Brno, Czech Republic). The concentrations of proteins S100A12 and HSP70 were determined by commercially available colorimetric sandwich enzyme-linked immunosorbent assay kits (Biovendor-Laboratorni medicina, and StressMarq, Victoria, BC, Canada). The analyses of S100A8, S100A12, HMGB1, and HSP70 had inter-assay coefficients of variation of 5.6%, 6.9%, 10.9%, and 11.3%, respectively. The total WBC count was determined in a local laboratory immediately after sampling.

Statistical analysis
--------------------

R software (version 3.3.1) was used for this post hoc analysis (coauthor MB) and to create the figures and tables. Numerical data are characterized as median and interquartile range. Categorical data are described as absolute and relative (%) frequencies. To assess significant differences between groups, two-sample Wilcoxon's test or Fisher's exact test was performed (for numerical and categorical data, respectively). The level of significance was defined as 0.05.

Results
=======

The final statistical analysis utilized data obtained from a total of 82 patients divided into the LPT (n=31) and LPS (n=51) groups according to the type of surgery. Almost all patients (93%, n=76) exhibited SIRS at some point during the first 3 days after admission. Only a small number developed sepsis (7%, n=6). The number of complications after surgery defined according to Clavien Dindo Classification did not differ between the groups. The description of surgical interventions according to the place of resection (upper, middle, and lower gastrointestinal tract) and the type of surgery (LPS, LPT), including the number of subjects is presented in [Table 2](#t2-tcrm-14-999){ref-type="table"}.

Baseline characteristics did not differ between the LPS and LPT groups. Comparing the clinical and surgical characteristics, we found significantly longer surgery time (*p*\<0.001), greater blood loss (*p*=0.04), and higher amounts of intraoperatively administered fluids (*p*=0.03) in the LPS group (sum of all laparoscopy subjects). The clinical outcomes that were followed, such as complications after surgery, ICU-LOS, H-LOS, in-hospital mortality, and 30-day mortality, did not differ between the two groups. The serum levels of alarmins (S100A8, S100A12, HMGB1, and HSP70) and biomarkers (WBC, CRP, and IL-6) in the LPS and LPT groups are given in [Table 3](#t3-tcrm-14-999){ref-type="table"}. We found no significant difference in serum alarmin levels between the two groups. We observed significantly higher levels of IL-6 on day 2 (*p*=0.03) and day 3 (*p*=0.04) in the LPS group.

Concerning the cancer subgroups, we found no differences in baseline characteristics between LPS and LPT. However, we observed significantly longer surgery time (*p*\<0.001), greater blood loss (*p*\<0.001), higher amounts of intraoperatively administered fluids (*p*\<0.01), and higher amounts of fresh frozen plasma administered (*p*=0.02) in the LPS cancer subgroup. In addition, ICU-LOS and H-LOS were significantly longer in the LPS cancer subgroup (*p*\<0.01 for both). Number of complications, in-hospital mortality, and 30-day mortality did not differ between subgroups.

We found significantly higher levels of S100A8 protein on day 1 (*p*=0.02) and day 2 (*p*=0.01), and S100A12 protein on day 2 (*p*=0.03) in the LPS cancer subgroup ([Figure 2](#f2-tcrm-14-999){ref-type="fig"}). We also observed significantly higher levels of IL-6 (*p*\<0.01, for all 3 days) in the LPS cancer subgroup ([Figure 3](#f3-tcrm-14-999){ref-type="fig"}).

Discussion
==========

Despite the benefits of solving the causal disease, elective major surgery causes iatrogenic trauma, eliciting a marked sterile immune response.[@b3-tcrm-14-999] The physiologic host response leads to wound healing and structural and functional restitution of a tissue. On the other hand, dysregulation of sterile inflammation can participate in the development of postoperative complications and adversely affect patient outcomes. In this study, we showed that the majority of subjects exhibited SIRS at some point during the first three consecutive days after elective MAS. This immune response to surgery and postoperative complications maybe influenced not only by injury caused by a surgeon but also by the presence of bacteria and/or bacterial products in the intestinal contents, with contamination of the surgical wound, blood, and so on. In our study, all subjects received routine antibiotic prophylaxis (β-lactam and metronidazole). Due to the low incidence of early postoperative sepsis (7%), we consider the anti-infective prophylaxis to be effective in decreasing the risk of infectious complications.

Our selection of the particular set of alarmins was based on their already known roles in inflammatory diseases.[@b18-tcrm-14-999]--[@b20-tcrm-14-999] S100A proteins are responsible for regulating the intracellular metabolism of calcium (Ca^2+^) and calcium-dependent signaling. The expression of S100A proteins is enhanced in inflamed tissues, where they activate endothelial and immune cells and facilitate the formation of local prothrombotic activity.[@b21-tcrm-14-999] HMGB1 binds to DNA and influences many nuclear processes (ie, activation of nuclear factor kappa B, repair of DNA); it is released from the injured cells and activates immunocytes. Heat shock proteins, including HSP70, bind to nascent polypeptide chains and facilitate their proper folding, working as chaperones for other danger signals and protecting cells against unfavorable conditions, primarily thermal stress.[@b22-tcrm-14-999] In preliminary data collection, we observed significantly higher levels of S100A8, S100A12, and HSP70 in surgical patients compared to healthy subjects.[@b23-tcrm-14-999] This suggests that alarmins participate in physiologic responses to surgical injury. Biomarkers, such as WBC count, CRP, IL-6, and albumin, reflect various types of injury, including infectious diseases, sterile trauma damage, and major surgery.[@b8-tcrm-14-999],[@b24-tcrm-14-999],[@b25-tcrm-14-999]

Laparoscopic procedures in gastrointestinal surgery are usually preferred to open surgery, especially due to the less invasiveness (smaller incision),[@b26-tcrm-14-999] less postsurgical pain, reduced risk of infectious complication, faster functional recovery, and better outcomes.[@b12-tcrm-14-999],[@b27-tcrm-14-999] To date, no study has evaluated the invasiveness of surgical procedures during MAS in relation to serum alarmin levels. We found no significant difference in alarmin levels between the LPS and LPT groups, including all surgical diagnoses. Therefore, overall degree of tissue injury reflected by alarmins seems to be similar in both types of surgical procedures.

Significantly higher levels of some alarmins (S100A8, S100A12) were obtained in the LPS cancer subgroup. This confirms a higher expression of S100A proteins in cancer,[@b28-tcrm-14-999] as reflected by their more pronounced systemic release after laparoscopic surgery for cancer.

Ramanathan et al described significantly higher CRP levels in patients undergoing extensive open resection of the large intestine, compared to laparoscopic procedures. CRP had no discriminative value related to postoperative infective complications. However, the authors did not describe some of the baseline (ie, weight, body mass index) and surgical characteristics (ie, duration of surgery, blood loss, use of vasopressors).[@b24-tcrm-14-999] On the contrary, we observed no differences in CRP levels between the colorectal resection subgroups during similar postoperative periods. Moreover, we found significantly higher levels of IL-6 in the LPS cancer subgroup, suggesting a greater inflammatory host response to laparoscopy, probably reflecting the longer surgery time and higher blood loss requiring higher amount of intraoperatively administered fluids.[@b29-tcrm-14-999],[@b30-tcrm-14-999] The different findings for CRP values maybe explained by the statistical error related to fewer subjects enrolled in our study and the potentially different baseline and surgical characteristics between the studies. Fretland et al studied the influence of the type of surgery (LPS/LPT) on changes in biomarker levels after liver resection for colorectal liver metastases. The authors found higher levels of HMGB1, IL-6, CRP, cell-free DNA, and macrophage inflammatory protein 1β in the open surgery group.[@b31-tcrm-14-999] This is again only in partial agreement with our study, because we found no difference in HMGB1 and CRP levels. These results may be explained by differences in organ-specific resections. However, we observed a significant difference in IL-6 laparoscopy group, suggesting a greater inflammatory response despite the levels of selected alarmins being similar. We suggest that a different set of alarmins other than those presently selected might be responsible for the observed inflammatory response.

We found significantly reduced ICU-LOS and H-LOS in the LPT cancer subgroup. These findings partially contradict the results reported by Zhuang et al, who described reduced H-LOS in cancer patients who underwent LPSs[@b32-tcrm-14-999] even in the setting of suboptimal use of the enhanced recovery after surgery protocol. Interestingly, we did not observe any significant differences in ICU-LOS and H-LOS between the LPS and LPT groups for all subjects undergoing MAS. We assume that this was due to the heterogeneity of the intervention used in different gastrointestinal sites and variability in the type and extensiveness of surgical diagnosis.

This study has several limitations. The first limitation is that it was designed as a post hoc analysis. The second limitation is the small numbers of subjects. Third, the intervals at which we sampled blood may not reflect exactly the dynamics of the blood concentration of alarmins. Fourth, a different set of alarmins may be responsible for the observed immune response, such as mitochondrial alarmins (mtDNA, *N*-formyl-Met-Leu-Phe); thus, the physiologic role of our selected set of alarmins in the development of inflammatory response could only be minor. Fifth, the various degrees and types of cancer as well as the position of gastrointestinal tract resection are potential sources of further bias.

Conclusion
==========

Both open surgery and laparoscopy can cause significant damage to the tissues. This study compares the degree of injury caused by these two main types of surgical procedures, as reflected by alarmins (danger signals and markers of tissue damage) and selected inflammatory biomarkers.

The degree of surgical injury elicited by open MAS as reflected by alarmins was similar to that of laparoscopic procedures. However, the laparoscopic surgery, especially for gastrointestinal cancer, seems to be injurious than open procedures, reflecting the longer surgery time and higher blood loss of the procedures. This is suggested by not only higher levels of biomarkers (IL-6) but also alarmins (S100A8 and S100A12), the markers of cellular damage more accurately estimating the degree of surgical injury.
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![CONSORT diagram of the study selection process.\
**Abbreviations:** CONSORT, Consolidated Standards of Reporting Trials; LPS, laparoscopy; LPT, open surgery (laparotomy).](tcrm-14-999Fig1){#f1-tcrm-14-999}

![The significant differences between LPS and LPT cancer subgroups related to proteins S100A8 and S100A12.\
**Abbreviations:** LPS, laparoscopy; LPT, open surgery (laparotomy); NS, not significant.](tcrm-14-999Fig2){#f2-tcrm-14-999}

![The significant differences between LPS and LPT cancer subgroups related to selected inflammatory biomarkers.\
**Abbreviations:** IL-6, interleukin-6; LPS, laparoscopy; LPT, open surgery (laparotomy).](tcrm-14-999Fig3){#f3-tcrm-14-999}

###### 

Baseline, clinical, surgical, and outcome characteristics

                                                                        LPT                    LPS                    All                    *p*-value
  --------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  General characteristics                                                                                                                    
   n                                                                    31                     51                     82                     
   Age, years                                                           64 (50.5--71)          63 (55.5--69.5)        63 (53.5--70)          0.90
   Sex, male                                                            21 (68%)               34 (67%)               55 (67%)               1.00
   Body weight, kg                                                      82 (70.5--85)          80 (67.5--90.5)        80 (68.5--89.5)        0.96
   Height, cm                                                           172 (168--180)         174 (167--178)         173 (167.25--178.75)   0.89
   Body mass index, kg/m^2^                                             25.95 (23.62--30.11)   27.44 (23.92--29.39)   26.33 (23.82--29.93)   0.77
  Clinical and surgical characteristics                                                                                                      
  ASA                                                                   2 (2--3)               2 (2--3)               2 (2--3)               0.62
   ASA I                                                                3 (10%)                3 (6%)                 6 (7%)                 0.67
   ASA II                                                               14 (45%)               27 (54%)               41 (51%)               0.50
   ASA III                                                              10 (32%)               18 (36%)               28 (35%)               0.81
   ASA IV                                                               4 (13%)                2 (4%)                 6 (7%)                 0.20
  APACHE II                                                             6.5 (5--10.5)          7 (5--10)              7 (5--10.25)           0.91
  SOFA (day 1)                                                          0 (0--2.75)            1 (0--3.75)            1 (0--3)               0.42
  SOFA (day 2)                                                          0 (0--1.25)            1 (0--3)               1 (0--3)               0.07
  SOFA (day 3)                                                          0 (0--1)               1 (0--3)               1 (0--3)               0.15
  SIRS                                                                  29 (94%)               47 (92%)               76 (93%)               1.00
  Sepsis                                                                4 (13%)                2 (4%)                 6 (7%)                 0.19
  Cancer                                                                18 (58%)               47 (92%)               65 (79%)               \<0.001
  Surgery, min                                                          220 (180--265)         320 (240--385)         275 (210--360)         \<0.001
  Blood loss, mL                                                        300 (100--525)         600 (175--1,050)       425 (100--1,000)       0.04
  Blood products (EBR), mL[a](#tfn2-tcrm-14-999){ref-type="table-fn"}   0 (0--125)             0 (0--550)             0 (0--537.5)           0.35
  Blood products (FFP), mL[a](#tfn2-tcrm-14-999){ref-type="table-fn"}   0 (0--0)               0 (0--555)             0 (0--509)             0.17
  Vasopressors                                                          11 (35%)               20 (39%)               31 (38%)               0.82
  Inotropes                                                             7 (23%)                13 (25%)               20 (24%)               1.00
  Fluids, mL                                                            2,900 (2,200--4,000)   4,000 (2,500--4,850)   3,500 (2,500--4,500)   0.03
  Mechanical ventilation after surgery                                  7 (23%)                13 (25%)               20 (25%)               1.00
  Body temperature at admission, °C                                     35.9 (35.8--36.2)      35.9 (35.6--36.1)      35.9 (35.7--36.2)      0.75
  Outcome                                                                                                                                    
  Complications after surgery                                           8 (26%)                23 (45%)               31 (38%)               0.45
  Clavien Dindo Classification, yes                                                                                                          
   Minor                                                                3 (10%)                11 (22%)               14 (17%)               0.23
   Major                                                                5 (16%)                12 (23%)               17 (21%)               0.58
   ICU-LOS, days                                                        4 (3--11.5)            6 (4--8)               6 (4--8)               0.29
   Hospital LOS, days                                                   15 (9--24)             16 (11--27)            16 (10--25.25)         0.36
   30-Day mortality                                                     1 (3%)                 6 (12%)                7 (9%)                 0.27
   In-hospital mortality                                                2 (6%)                 7 (14%)                9 (11%)                0.47

**Notes:** The qualitative variables are expressed as n (%) and quantitative variables as the median (25th--75th percentile).

Administered during surgery.

**Abbreviations:** ASA, American Society of Anesthesiology; APACHE, Acute Physiology and Chronic Health Evaluation; EBR, erythrocyte concentrate without buffy coat; FFP, fresh frozen plasma; ICU, intensive care unit; LOS, length of stay; LPS, laparoscopy; LPT, open surgery (laparotomy); SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment.

###### 

The description of surgical interventions according to the place of resection (upper, middle, lower GIT) and the type of surgery (LPS, LPT), including the number of subjects

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GIT level                                                                             Type of surgery                                        LPT   LPS   All        
  ------------------------------------------------------------------------------------- ------------------------------------------------------ ----- ----- ----- ---- ------
  Upper                                                                                 Esophageal and gastric resection                       3     1     12    1    17

  Middle                                                                                Pancreatic (duodenopancreatic) and hepatic resection   1     0     8     0    9

  Other small intestinal resections (cystectomy, status ileosus, gynecologic surgery)   0                                                      8     10    0     18   

  Lower                                                                                 Large intestine and rectum resection                   14    4     17    3    38\
                                                                                                                                                                      n=82
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** GIT, gastrointestinal tract; LPS, laparoscopy; LPT, laparotomy.

###### 

Serum levels of alarmins (S100A8, S100A12, HMGB1, and HSP70) and biomarkers (CRP, IL-6, albumin, and WBC) in the LPS and LPT groups three consecutive days after surgery

                  LPT                     LPS                    *p*-value
  --------------- ----------------------- ---------------------- -----------
  S100A8, ng/m    L                                              
   Day 1          1.1 (0.98--1.7)         1.24 (0.93--1.68)      0.50
   Day 2          1.13 (0.86--1.99)       1.45 (0.98--1.79)      0.35
   Day 3          1.04 (0.83--1.62)       1.21 (0.77--1.84)      0.68
  S100A12, ng/m   L                                              
   Day 1          89.4 (75.2--101.35)     93 (59--138.6)         0.94
   Day 2          96.4 (86.8--116.5)      120.3 (70.75--156.5)   0.24
   Day 3          98.05 (76.88--122.75)   110.5 (71.4--170.15)   0.42
  HSP70, ng/m     L                                              
   Day 1          5.34 (4.21--7.33)       7.64 (4.82--10.29)     0.06
   Day 2          4.72 (3.46--7)          5.3 (4.08--8.14)       0.21
   Day 3          5.13 (3.42--6.46)       4.68 (3.16--7.13)      0.99
  HMGB1, U/m      L                                              
   Day 1          14 (4--46.5)            12 (4--58.5)           0.83
   Day 2          14 (4--36.5)            11 (4--50.5)           0.90
   Day 3          15.5 (4--40)            10 (4--49.5)           0.95
  WBC count, ×    10^9^/L                                        
   Day 1          9.8 (8.5--11.8)         9.9 (8.5--12.75)       0.80
   Day 2          9.4 (6.65--12.65)       10 (8.4--12.25)        0.47
   Day 3          8.6 (5.9--12.15)        8.6 (6.9--11.8)        0.60
  CRP, mg/L                                                      
   Day 1          115 (88--129.5)         109 (73.5--135.5)      0.96
   Day 2          181 (130.5--221)        184 (141--212.5)       0.82
   Day 3          146 (104.5--190)        145 (114.5--214.5)     0.33
  IL-6, ng/L                                                     
   Day 1          111 (63.65--278.5)      149 (110.5--281)       0.13
   Day 2          69.1 (28.4--109.5)      95.2 (54.9--155.5)     0.03
   Day 3          31.3 (16.95--48.85)     45.8 (23.45--93.5)     0.04

**Note:** The variables are expressed as the median (25th--75th percentile).

**Abbreviations:** CRP, C-reactive protein; HMGB1, high mobility group box 1; HSP70, heat shock protein 70; IL-6, interleukin-6; LPS, laparoscopy; LPT, open surgery (laparotomy); WBC, white blood cell.
